Investor Presentaiton

R&D investor presentation Semaglutide 2.4mg showed strong weight loss across the STEP programme STEP 1 Weight mgmt STEP 3 Weight mgmt with IBT STEP 4 Sustained weight mgmt After 68 weeks After 20 weeks 105.8 107.2 96.1 Baseline body weight Sema 105.3 Change from baseline in BW (%) STEP 2 Weight mgmt with T2D 99.8 -6 -8 864202 +6%! Placebo Sema IBT Sema + IBT Placebo Sema Placebo 6.5 Sema -2.4 -5.0 -5.2 -10 * -8.8 -12 * -10.6* -14 -16 -18 * -16.9* -17.6* -18.2 *Statistically significant, based on the trial product estimand (secondary statistical approach): treatment effect if all people adhered to treatment and did not initiate other anti-obesity therapies IBT: Intensive behavioural therapy; Mgmt: Management; Sema: Semaglutide; BW: Body weight; T2D: Type 2 diabetes Placebo -3.1 32

View entire presentation